Hos gravide rotter resulterede systemisk administration af travopost på doser mere end 200 gange højere end den kliniske dosis gennem organogeneseperioden i et forøget antal misdannelser.
In pregnant rat, systemic administration of travoprost at doses more than 200 times the clinical dose during the period of organogenesis resulted in an increased incidence of malformations.